Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 9/20 | 0.44 |
| ▸ | CDC7 | O00311 | 6/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.44 |
| ▸ | CDK8 | P49336 | 5/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.44 |
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.44 |
| ▸ | PRKACA | P17612 | 4/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | MELK | Q14680 | 3/20 | 0.44 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.44 |
| ▸ | CLK2 | P49760 | 3/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.44 |
| ▸ | CDK9 | P50750 | 3/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.44 |
| ▸ | CDK7 | P50613 | 2/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13306482 | 0.83 | PDPK1 (0.45) | ROCK1CDC7CLK4ROCK2DYRK1A | |
| SCHEMBL27678743 | 0.83 | ROCK1 (0.52) | ROCK1CDC7CLK4ROCK2DYRK1A | |
| SCHEMBL13887849 | 0.79 | CLK4 (0.62) | ROCK1CDC7CLK4ROCK2DYRK1A | |
| SCHEMBL859005 | 0.78 | CAMKK2 (0.57) | CDC7CLK4ROCK2DYRK1ACDK8 | |
| SCHEMBL4478021 | 0.77 | CYP3A4 (0.53) | ROCK1CDC7CLK4ROCK2DYRK1A | |
| SCHEMBL13887827 | 0.77 | ROCK1 (0.70) | ROCK1DYRK1ACDK2CDK5RPS6KA3 | |
| SCHEMBL13306445 | 0.76 | PDPK1 (0.53) | ROCK1CDC7CLK4ROCK2DYRK1A | |
| SCHEMBL13306455 | 0.75 | ROCK1 (0.49) | ROCK1DYRK1ACDK2CDK5RPS6KA3 | |
| SCHEMBL31341012 | 0.74 | CDK5 (0.57) | CDK2CDK5SREBF2 | |
| SCHEMBL3258037 | 0.74 | CDK5 (0.55) | ROCK1DYRK1ACDK2CDK5SREBF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1756108-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-05 | — | — | US | disclosed |
| WO-2005103050-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | ROCK2, ROCK1, TNK2 | ROCK1 2/4885CDC7 243/4885CLK4 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.